A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of DigiFab® in Antepartum Subjects With Severe
Phase of Trial: Phase II/III
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Anti-digoxin polyclonal antibody (Primary)
- Indications Preeclampsia
- Focus Registrational; Therapeutic Use
- Sponsors Velo Bio
- 23 Oct 2017 Planned End Date changed from 1 Oct 2018 to 1 Dec 2019.
- 23 Oct 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2019.
- 01 Jun 2017 According to an AMAG Pharmaceuticals media release, first patient has been enrolled in the trial.